A share price of Soleno Therapeutics Inc [SLNO] is currently trading at $69.95, up 1.88%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SLNO shares have gain 4.56% over the last week, with a monthly amount glided 3.48%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Soleno Therapeutics Inc [NASDAQ: SLNO] stock has seen the most recent analyst activity on October 07, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $125. Previously, Wells Fargo started tracking the stock with Overweight rating on August 20, 2025, and set its price target to $123. On June 23, 2025, TD Cowen initiated with a Buy rating and assigned a price target of $110 on the stock. Stifel reiterated its recommendation of a Buy but $74 remained the price target by the analyst firm on December 02, 2024. Robert W. Baird reiterated a Outperform rating for this stock on December 02, 2024, but kept the price target unchanged to $72. In a note dated September 03, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $70 on this stock.
Soleno Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $41.50 and $90.32. Currently, Wall Street analysts expect the stock to reach $123 within the next 12 months. Soleno Therapeutics Inc [NASDAQ: SLNO] shares were valued at $69.95 at the most recent close of the market. An investor can expect a potential return of 75.84% based on the average SLNO price forecast.
Analyzing the SLNO fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -5.87%, Pretax Profit Margin comes in at -5.54%, and Net Profit Margin reading is -5.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -0.74 and Total Capital is -0.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 67.31 points at the first support level, and at 64.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 71.27, and for the 2nd resistance point, it is at 72.60.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Soleno Therapeutics Inc [NASDAQ:SLNO] is 15.13. In addition, the Quick Ratio stands at 15.01 and the Cash Ratio stands at 3.65. Considering the valuation of this stock, the price to sales ratio is 113.82, the price to book ratio is 14.69.
Transactions by insiders
Recent insider trading involved Abingworth Bioventures VII LP, Shareholder, that happened on Aug 11 ’25 when 1.35 million shares were purchased. Hirano Patricia C completed a deal on Jul 01 ’25 to sell 3830.0 shares. Meanwhile, Officer PATRICIA HIRANO bought 3830.0 shares on Jul 01 ’25.
